The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•30 April 2026•

1 min read

ProQR Nominates Dr. Lykke Hinsch Gylvin to Board to Boost RNA Pipeline

Key Facts

1ProQR Therapeutics nominated Dr. Lykke Hinsch Gylvin, Chief Medical Officer at Boehringer Ingelheim, to its Board of Directors.

2The nomination aims to strengthen the company's global drug development expertise as it advances its Axiomer RNA editing pipeline.

ProQR Therapeutics has officially nominated Dr. Lykke Hinsch Gylvin, the current Chief Medical Officer at Boehringer Ingelheim, to join its Board of Directors as an independent non-executive member. This strategic nomination is designed to leverage Dr. Gylvin’s 20 years of extensive experience in global drug development and clinical strategy. The move comes as ProQR seeks to strengthen its leadership team to support the advancement of its proprietary Axiomer RNA editing pipeline. Adding a high-profile industry veteran is considered a positive governance signal for the biotech firm as it enters a critical growth phase. Her expertise is expected to provide significant oversight for the company’s clinical programs and international expansion efforts.